Faculty profile
Mariana Baz Etchebarne
Back to facultyThis profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a Université Laval directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $1,212,526
Optimizing treatments for influenza in vulnerable populations using an immunocompromised ferret model.
CIHR · 2026 · Nominated PI
- $300,000
The Pursuit of a SARS-CoV-2 Vaccine: Aiming for Broad Protection
CIHR · 2024 · Co-investigator
- $150,000
Is treatment with a combination of licensed influenza antivirals superior to monotherapy for highly pathogenic H5N1 influenza virus from cattle?
CIHR · 2024 · Nominated PI
Optimizing treatments for influenza in vulnerable populations using an immunocompromised ferret model.
Principal investigators: Baz Etchebarne, Mariana
Keywords: Aerosol Transmission; Antiviral; Antiviral Resistance; Epithelial Cells; Ferrets; Histopathology; Immunomodulators; Influenza Virus; Pathogenesis; Transcriptomics
The Pursuit of a SARS-CoV-2 Vaccine: Aiming for Broad Protection
Principal investigators: Leclerc, Denis
Keywords: Flexuous Rod Shape Nanoparticle; Humoral And T Cell Immune Response; Sars-C0v-2 Kp.3 Variant; Sars-Cov-2 Nucleocapsid; Sars-Cov-2 Receptor Binding Domain; Sars-Cov-2 Vaccine; Sorties Mediated Coupling; Toll Like Receptor 7/8 Agonist; Vaccine Platform; Vaccine With Broad Protection
Is treatment with a combination of licensed influenza antivirals superior to monotherapy for highly pathogenic H5N1 influenza virus from cattle?
Principal investigators: Baz Etchebarne, Mariana
Keywords: Aerosol Transmission; Antiviral Resistance; Bioinformatics; Fda Approved Antivirales; Hamsters; Highly Pathogenic Avian Influenza; Histopathology; Nose And Small And Large-Airway; Pathogenesis; Zoonotic Viruses
Preclinical proof of concept studies of a new generation of TLR7/8 agonist used in prevention against respiratory viruses and in immunotherapy against lung cancer.
Principal investigators: Leclerc, Denis
Keywords: Innate Immunity; Lung Cancers; Nanoparticles; Non Small Cell Lung Cancer (Nsclc); Nsclc Immunotherapy; Prevention Implantation Cancer Cells; Prevention Respiratory Viral Infections; Respiratory Viruses; Sars-Cov-2; Tlr 7/8 Agonist
Canada Research Chair - Tier 2
Principal investigators: Baz Etchebarne, Mariana
Keywords: Crc
COVID-19 Variant Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus
Principal investigators: Boivin, Guy; Baz Etchebarne, Mariana; Lin, Sheng-Xiang
Keywords: Antivirals; Combination; Coronavirus; Ferret; Hamster; Modeling; Polymerase; Repurposing; Synergy; Transcriptomic
Prevention of the immunopathology induced by SARS-CoV-2
Principal investigators: Estaquier, Jérôme; Baz Etchebarne, Mariana; Droit, Arnaud; Papadopoulou, Barbara
Keywords: Biomarker; Caspase; Cell Death; Hamster; Inflammation; Interferon; Omics; Pathogenesis; Sars-Cov-2; Therapy
COVID-19 Variant Network - Innovative therapeutic approaches for the 2019-novel coronavirus
Principal investigators: Boivin, Guy; Finzi, Andrés; Liang, Chen; Lin, Sheng-Xiang
Keywords: Antivirals; Combination; Coronavirus; Ferret; Hamster; Modeling; Polymerase; Repurposing; Synergy; Transcriptomic
Innovative therapeutic approaches for the 2019-novel coronavirus
Principal investigators: Boivin, Guy; Lin, Sheng-Xiang
Keywords: Antivirals; Combination; Coronavirus; Ferret; Hamster; Modeling; Polymerase; Repurposing; Synergy; Transcriptomic
Sex as a Biological Variable Supplement - Innovative therapeutic approaches for the 2019-novel coronavirus
Principal investigators: Boivin, Guy; Lin, Sheng-Xiang
Keywords: Antivirals; Combination; Coronavirus; Ferret; Hamster; Modeling; Polymerase; Repurposing; Synergy; Transcriptomic
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.